Name: Nifedipine
Brand: Selleck Chemicals
SKU: S1808
Availability: InStock
Rating: 5 (16 reviews)

Jump to

Quality Control

Batch: Purity: 99.69%

99.69

Related Targets	CFTR CRM1 CD markers AChR Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase GluR
Other Calcium Channel Inhibitors	Bay K 8644 BAPTA-AM Tetrandrine Flunarizine 2HCl Nilvadipine Cilnidipine YM-58483 (BTP2) Ionomycin Imperatorin Manidipine 2HCl

Solubility

In vitro
Batch:

DMSO : 69 mg/mL (199.23 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 15 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.000mg/ml (11.55mM)	Taking the 1 mL working solution as an example, add 50 μL of 80 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.000mg/ml (11.55mM)	Taking the 1 mL working solution as an example, add 50 μL of 80 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	346.33	Formula	C₁₇H₁₈N₂O₆	Storage (From the date of receipt)	2 years 4°C(in the dark) powder
CAS No.	21829-25-4	Download SDF		Storage of Stock Solutions	Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.
Synonyms	BAY-a-1040			SMILES	CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC

Read more about storage stability CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	calcium channel
In vitro	Nifedipine causes a significant concentration-dependent increase in eNOS protein expression by cultured human coronary artery endothelial cells. This compound antagonizes L-type Ca+ channels found throughout the cardiovascular system, but also blocks Kv channels, which are members of the same supergene family. It dose-dependently decreases the values of [(3)H]-thymidine incorporation and total cellular protein content as well as the levels of phosphorylated extracellular signal-regulated protein kinase (ERK) 1/2, mitogen-activated protein kinase kinase (MEK) 1/2, and even the phosphorylation of Pyk2, in vascular smooth muscle cells (VSMC). This chemical suppresses the levels of proliferative cell nuclear antigen (PCNA) dose-dependently in both VSMC and balloon-injured thoracic aortae in VSMC.
In vivo	Nifedipine (3 mg/kg) slightly lowers the level of systolic and/or diastolic blood pressure or increased the heart rate in rats. This compound (1 μm) produces a maximal inhibition of the store-operated pathway in choroidal arteriolar smooth muscle. This chemical (20 and 40 mg/kg) markedly prevents the HCl plus ethanol-induced gastric mucosal injury and the increase in the content of thiobarbituric acid-reactive substances in the injured mucosa in rats. It (20 and 40 mg/kg) dose-dependently promotes the ulcer healing and inhibites the increase in the content of thiobarbituric acid-reactive substances in the ulcerated mucosa in rats.
References	[1] https://pubmed.ncbi.nlm.nih.gov/10640297/ [2] https://pubmed.ncbi.nlm.nih.gov/9190860/ [3] https://pubmed.ncbi.nlm.nih.gov/11139427/ [4] https://pubmed.ncbi.nlm.nih.gov/11313433/ [5] https://pubmed.ncbi.nlm.nih.gov/9920200/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-03)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07363343	RECRUITING	Hypertension; Postpartum Preeclampsia	The Cleveland Clinic	2026-03-10
NCT06220721	RECRUITING	Hypertension, Pregnancy-Induced	Medical College of Wisconsin	2024-10-23
NCT07023003	RECRUITING	Hypertension in Pregnancy	Nebraska Methodist Health System	2025-07-11	PHASE4
NCT05551104	RECRUITING	Postpartum Complication; Maternal Hypertension; High Blood Pressure	Loma Linda University	2023-05-08	PHASE3
NCT06915792	RECRUITING	Postpartum Hypertension (PPHT)	University of California, Los Angeles	2025-06-01	PHASE4
NCT05989581	RECRUITING	Hypertension in Pregnancy	University of Alabama at Birmingham	2024-04-24	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Nifedipine Calcium Channel inhibitor

Chemical Structure

Molecular Weight: 346.33